Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07282717

Fibroblast Line Evaluation for COL5A eXpression and Thoracic Aortic Aneurysms: in Vitro Characterization of Cutaneous Fibroblasts in Adult Patients

This study examines adults with COL5A gene mutations to understand why some develop aortic aneurysms while others do not. Participants provide a small skin biopsy, and researchers analyze fibroblasts to evaluate collagen production, extracellular matrix organization, and connective-tissue signaling pathways. The goal is to identify biological differences that may explain variable vascular risk and support future personalized monitoring and treatment strategies.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cardiovascular Genetic Centre IRCCS Policlinico San Donato

San Donato Milanese, Italy, 20097

Location status: Recruiting

Location contact

Alessandro Pini, MD

PRINCIPAL_INVESTIGATOR

Nathasha Samali UDUGAMPOLAGE

CONTACT

[email protected]

(+39) 02 52774705

About this study

Individuals with mutations in the collagent type V, alpha (COL5A) gene show variable clinical outcomes. While some develop aortic aneurysms, others with the same mutation remain free of cardiovascular complications. The mechanisms driving this variability are not fully understood.

This study aims to investigate biological differences at the cellular level by analyzing fibroblasts derived from a small skin biopsy. Fibroblasts play a key role in the production and organization of type V collagen and the extracellular matrix.

Researchers will:

Grow fibroblasts from participants' skin samples.

Assess cell growth, migration, and extracellular matrix formation.

Measure the quantity and type of collagen produced.

Evaluate molecules involved in collagen breakdown and repair.

The study compares individuals with COL5A mutations who have documented aortic aneurysms to those with the same mutation but no vascular involvement. Analyses will also consider differences among family members who share the same genetic variant.

By characterizing fibroblast behavior, the study seeks to clarify why some individuals develop aortic disease while others remain unaffected. Findings may help identify cellular features associated with increased or reduced vascular risk and guide future strategies for monitoring, prevention, and personalized care in patients with COL5A mutations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects aged 18 and above
  • Mutation in COL5A
  • Signed informed consent

Exclusion criteria

  • Corticosteroid or Steroids or Fluorochinolones treatment within six months before enrollment
  • Subjects on chronic immunosuppressive therapies such as oral steroids, but also on chronic topical steroids in the area of investigation
  • Subject on anticoagulant therapy
  • History of coagulation factor defects/alterations (data found in anamnesis and medical records)
  • A history of keloid formation (data found in anamnesis and medical records)
  • Anesthetic drug allergy (data found in anamnesis and medical records)

Treatment and study plan

Primary outcomes

  1. Fibroblasts phenotype

    Time frame: 24 months

    In vitro characterization and evaluation of fibroblasts phenotype in adult patients with COL5A mutations with or without aortic involvement (ascending and descending aortic aneurysms)

  2. Differences molecular mechanisms in collagen

    Time frame: 24 months

    Identify differences in molecular mechanisms involved in collagen and ECM turnover pathways between family members according to the vascular manifestation and the genetic mutation in COL5A gene

Study contacts

Contact information is provided by the study sponsor or research team.

Alessandro Pini Alessandro Giorgio Pini,MD, Medical degree

CONTACT

[email protected]

+39 0252774705

Nathasha Samali Udugmpolage

CONTACT

[email protected]

+39 0252774705

Sponsors and collaborators

Lead sponsor

IRCCS Policlinico S. Donato

Other

Registry information

Acronym: FLEX5 project

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Dec 15, 2025
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.